Organon terminates ebopiprant license agreement with XOMA; XOMA to seek new partner

XOMA Royalty Corp

Organon notified XOMA of intent to terminate License Agreement for ebopiprant; effective Jan 21, 2024.
Termination is for convenience; no milestone payments for achievements after notice; no early termination penalties.
XOMA to seek to out-license ebopiprant for further development.
License agreement originally between Organon and ObsEva (July 2021), assumed by XOMA in Nov 2022.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

XOMA Royalty Corp terminated License Agreement (ebopiprant) with Organon International GmbH valued at Termination for convenience; no material penalties; Company to seek out-license (effective 2023-10-23).

Action: termination
Agreement: license
Counterparty: Organon International GmbH
Value: Termination for convenience; no material penalties; Company to seek out-license
Effective: 2023-10-23

Exact text from the filing

On October 23, 2023, Organon International GmbH (“Organon”), notified XOMA Corporation (the “Company”) of its intent to terminate for convenience that certain License Agreement, by and between Organon and ObsEva SA (“ObsEva”), dated July 26, 2021 (the “License Agreement”).

View on SEC.gov

38 material agreements filed in the last 30 days. Browse all material agreements →

XOMA Royalty Corp filing history →

Source: SEC EDGAR

accession 0001193125-23-265233

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.